Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10451601 | 1.00 | HIF1A (0.53) | HIF1ATSHRFAAHTRPV1GPR84 | |
| SCHEMBL1958540 | 1.00 | HIF1A (0.53) | HIF1ATSHRFAAHTRPV1GPR84 | |
| SCHEMBL13287154 | 1.00 | HIF1A (0.53) | HIF1ATSHRFAAHTRPV1GPR84 | |
| SCHEMBL973120 | 1.00 | — | — | |
| SCHEMBL19816822 | 1.00 | HIF1A (0.53) | HIF1ATSHRFAAHTRPV1GPR84 | |
| 1,6-Hexanediol SCHEMBL8450098 | 1.00 | HIF1A (0.53) | HIF1ATSHRFAAHTRPV1GPR84 | |
| SCHEMBL1958838 | 1.00 | HIF1A (0.53) | HIF1ATSHRFAAHTRPV1GPR84 | |
| SCHEMBL9407145 | 1.00 | — | — | |
| SCHEMBL2458519 | 1.00 | HIF1A (0.53) | HIF1ATSHRFAAHTRPV1GPR84 | |
| SCHEMBL187920 | 1.00 | HIF1A (0.53) | HIF1ATSHRFAAHTRPV1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110087621-B | O/W emulsions comprising a C16-C30 fatty alcohol, an anionic surfactant, an oil, a wax, and a hydrophilic solvent | 欧莱雅 | 2022-07-08 | — | — | CN | claimed |
| US-4097665-A | Diacylnucleosides and process for preparing the same | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JA) | 1978-06-27 | — | — | US | claimed |
| EP-4746862-A2 | ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS | Aquestive Therapeutics, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-122075448-A | Pharmaceutical composition with enhanced permeation | — | 2026-05-26 | — | — | CN | disclosed |
| WO-2026090119-A1 | PHARMACEUTICAL FILM STORAGE AND DISPENSER DEVICE | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260108458-A1 | METHODS OF ADMINISTERING ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS TO TREAT ALLERGY | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108422-A1 | PHARMACEUTICAL FILM STORAGE AND DISPENSER DEVICE | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260027045-A1 | METHODS OF ADMINISTERING ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-01-29 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-12433850-B2 | Enhanced delivery epinephrine and prodrug compositions | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-12427121-B2 | Enhanced delivery epinephrine compositions | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| WO-2007035901-A2 | BIFUNCTIONAL CATALYSTS FOR ISOMERIZATION OF UNSATURATED HYDROCARBONS | SAN DIEGO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-03-29 | — | — | WO | disclosed |
| US-5691319-A | ANTICARCINOGENIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-11-25 | — | — | US | disclosed |
| CN-1033227-C | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and their use. | SANKYO CO (JP) | 1996-11-06 | — | — | CN | disclosed |
| EP-0536936-B1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | SANKYO CO (JP) | 1996-08-14 | — | — | EP | disclosed |
| EP-0640105-A1 | ADHESIVE AGENT CONTAINING POLYSILOXANE-GRAFTED POLYMER, AND COSMETIC COMPOSITIONS THEREOF | THE PROCTER & GAMBLE COMPANY (US) | 1995-03-01 | — | — | EP | disclosed |
| WO-1993023446-A2 | ADHESIVE AGENT CONTAINING POLYSILOXANE-GRAFTED POLYMER, AND COSMETIC COMPOSITIONS THEREOF | THE PROCTER & GAMBLE COMPANY (US) | 1993-11-25 | — | — | WO | disclosed |
| CN-1072686-A | Has Pyrmidine nucleoside derivatives of anti-tumor activity and its production and use | SANKYO CO (JP) | 1993-06-02 | — | — | CN | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
| US-4097665-A | Diacylnucleosides and process for preparing the same | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JA) | 1978-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12433850-B2 | Enhanced delivery epinephrine and prodrug compositions | ADRA2C, ADRB3, ADRA1B | HIF1A 2399/4885TSHR 2984/4885FAAH 483/4885 |
| US-20260108458-A1 | METHODS OF ADMINISTERING ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS TO TREAT ALLERGY | ADRB1, ADRB2, ADRA1D | HIF1A 3499/4885TSHR 393/4885FAAH 491/4885 |
| US-20260108422-A1 | PHARMACEUTICAL FILM STORAGE AND DISPENSER DEVICE | ICAM1, GJA1, ICOS | HIF1A 152/4885TSHR 1493/4885FAAH 1615/4885 |
| US-20260027045-A1 | METHODS OF ADMINISTERING ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS | ADRB1, ADRB2, ADRA1D | HIF1A 2578/4885TSHR 718/4885FAAH 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.